ArticleTH open : companion journal to thrombosis and haemostasis2026
Time in Therapeutic Range in Patients with Venous Thromboembolism on Vitamin K Antagonist in a Moroccan Thrombosis Unit : An Observational Study.
Article in TH open : companion journal to thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with venous thromboembolism (VTE) frequently require vitamin K antagonists (VKAs) to treat and prevent recurrent events. Aims: We performed a study to assess the quality of anticoagulation in patients with VTE treated with VKAs using time in therapeutic range (TTR), to identify associated factors with predictors of poor control and outcomes in VTE patients. Methods: We performed an observational, retrospective study that included VTE patients treated with VKA. The primary outcome was the TTR calculated according to the Rosendaal algorithm. Results: A total of 171 VKA-treated patients were evaluated (53.2% men). The average age of our patients at diagnosis was 49.8 + 16.6 years [17-92]. VTE's most common location was the lower limbs, with 91.8% cases, proximal in 83.6%. Patients were followed for a mean period of 178 days. The mean TTR was 41.2% (standard deviation: 32.9%), and 74.3% of the patients had a mean TTR < 65%. The rates of major bleeds and thromboembolic events were 0.5 and 2.2%, respectively. After multivariate statistical analysis, age older than 65 and surgery provoked VTE were associated with better TTR. Conclusions: These results are informative and may help identify patients who require closer monitoring or innovative strategies to optimize oral anticoagulant therapy outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.